Education
About Us
Working with TipRanks
Follow Us
BioVaxys Technology (TSE:BIOV)
:BIOV
Total Valuation
BioVaxys Technology has a market cap or net worth of $7.43M. The enterprise value is C$5.96M.
Market Cap$7.43M
Enterprise ValueC$5.96M
Share Statistics
BioVaxys Technology has 29,152,520 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,152,520
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BioVaxys Technology’s return on equity (ROE) is 2.06 and return on invested capital (ROIC) is 177.94%.
Return on Equity (ROE)2.06
Return on Assets (ROA)-3.04
Return on Invested Capital (ROIC)177.94%
Return on Capital Employed (ROCE)1.72
Revenue Per Employee―
Profits Per Employee-10.00T>
Employee Count―
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BioVaxys Technology is ―. BioVaxys Technology’s PEG ratio is 0.05.
PE Ratio―
PS Ratio0.00
PB Ratio-7.14
Price to Fair Value-7.14
Price to FCF-4.69
Price to Operating Cash Flow-2.29
PEG Ratio0.05
Income Statement
In the last 12 months, BioVaxys Technology had revenue of 0.00 and earned -3.95M in profits. Earnings per share was -0.20.
Revenue0.00
Gross Profit0.00
Operating Income-3.30M
Pretax Income-3.95M
Net Income-3.95M
EBITDA-3.95M
Earnings Per Share (EPS)-0.20
Cash Flow
In the last 12 months, operating cash flow was -2.97M and capital expenditures 0.00, giving a free cash flow of -2.97M billion.
Operating Cash Flow-2.97M
Free Cash Flow-2.97M
Free Cash Flow per Share-0.10
Dividends & Yields
BioVaxys Technology pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.22
52-Week Price Change-56.00%
50-Day Moving Average0.25
200-Day Moving Average0.33
Relative Strength Index (RSI)47.76
Average Volume (3m)20.26K
Important Dates
BioVaxys Technology upcoming earnings date is Mar 26, 2026, Before Open (Confirmed).
Last Earnings DateOct 2, 2025
Next Earnings DateMar 26, 2026
Ex-Dividend Date―
Financial Position
BioVaxys Technology as a current ratio of 0.40, with Debt / Equity ratio of -4.90%
Current Ratio0.40
Quick Ratio0.40
Debt to Market Cap<0.01
Net Debt to EBITDA0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BioVaxys Technology has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
BioVaxys Technology EV to EBITDA ratio is -3.43, with an EV/FCF ratio of -4.64.
EV to Sales0.00
EV to EBITDA-3.43
EV to Free Cash Flow-4.64
EV to Operating Cash Flow-7.28
Balance Sheet
BioVaxys Technology has $4.08K in cash and marketable securities with $133.72K in debt, giving a net cash position of -$129.64K billion.
Cash & Marketable Securities$4.08K
Total Debt$133.72K
Net Cash-$129.64K
Net Cash Per Share>-$0.01
Tangible Book Value Per Share-$0.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for BioVaxys Technology is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast25.09%